GEMFIBROZIL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H22O3
Molecular Weight	250.3334
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(OCCCC(C)(C)C(O)=O)=C(C)C=C1

InChI

InChIKey=HEMJJKBWTPKOJG-UHFFFAOYSA-N

InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H22O3
Molecular Weight	250.3334
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.drugbank.ca/drugs/DB01241
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf

Gemfibrozil, a fibric acid antilipemic agent similar to clofibrate, is used to treat hyperlipoproteinemia and as a second-line therapy for type IIb hypercholesterolemia. It acts to reduce triglyceride levels, reduce VLDL levels, reduce LDL levels (moderately), and increase HDL levels (moderately). Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. It does so by activating Peroxisome proliferator-activated receptor-alpha (PPARα) 'transcription factor ligand', a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Gemfibrozil also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. Gemfibrozil is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Solute carrier organic anion transporter family member 1B1 30 Target ID: CHEMBL1697668 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16316932	Inhibitor 8146	12.5 µM [Ki]
Cytochrome P450 2C9 50 Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16299161	Inhibitor 8146	30.0 µM [IC50]
Cytochrome P450 2C8 18 Target ID: CHEMBL3721 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16176562	Inhibitor 8146	30.4 µM [Ki]
Peroxisome proliferator-activated receptor alpha 61 Target ID: CHEMBL239 Sources: http://www.drugbank.ca/drugs/DB01241	Agonist 2637	59.0 µM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperlipidemia 75 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf	Primary		Approved 8307	LOPID Approved Use LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides Launch Date 3.77654411E11
Coronary heart disease 22 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018422s055lbl.pdf	Preventing		Approved 8307	LOPID Approved Use LOPID (gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides Launch Date 3.77654411E11

C_max

Value	Dose	Co-administered	Analyte	Population
28 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
17400 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01736254	600 mg single, oral dose: 600 mg route of administration: oral experiment type: single co-administered:		GEMFIBROZIL plasma	Homo sapiens population: healthy age: sex: food status:

AUC

Value	Dose	Co-administered	Analyte	Population
104 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19648824	600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered:		GEMFIBROZIL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	Disc. AE: Depression, Flushing... AEs leading to discontinuation/dose reduction: Depression (1.1%) Flushing (1.1%) Nausea (2.2%) Vomiting (1.1%) Rash (1.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	Disc. AE: Abdominal cramps, Abnormal liver function tests... AEs leading to discontinuation/dose reduction: Abdominal cramps Abnormal liver function tests Diarrhea CPK increased Joint pain Muscle pain Nausea Vomiting Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13

AEs

AE	Significance	Dose	Population
Depression	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Flushing	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Rash	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Vomiting	1.1% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Nausea	2.2% Disc. AE	600 mg 2 times / day multiple, oral Recommended Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198	unhealthy, 59 n = 87 Health Status: unhealthy Condition: Non-insulin-dependent diabetes mellitus Age Group: 59 Sex: M+F Population Size: 87 Sources: https://pubmed.ncbi.nlm.nih.gov/7614520 Page: p.198
Abdominal cramps	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Abnormal liver function tests	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
CPK increased	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Diarrhea	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Joint pain	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Muscle pain	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Nausea	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13
Vomiting	Disc. AE	9 g single, oral Overdose Dose: 9 g Route: oral Route: single Dose: 9 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf Page: p.13

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1532	inhibitor 1695	inhibitor 1789

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 770 OATP2B1 121 OATP1B3 691 OAT3 625 MRP2 363 P-gp 1401 CYP2C8 869 CYP2C19 1410 CYP1A2 1463 CYP2A6 670 CYP2E1 846	P-gp 1491 UGT1A1 417 UGT1A3 421 UGT1A4 345 UGT1A6 306 UGT1A7 235 UGT1A8 282 UGT1A9 378 UGT1A10 289 UGT2B4 248 UGT2B7 387 UGT2B15 202 UGT2B17 212

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2A6 702	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP2D6 1826	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP2E1 929	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
CYP3A4 1857	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	no
MRP2 452	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/17523051/\|https://pubmed.ncbi.nlm.nih.gov/16316932/	no
P-gp 1588	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/16316932/\|https://pubmed.ncbi.nlm.nih.gov/14698041/	no
OAT3 627	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/21383204/\|https://pubmed.ncbi.nlm.nih.gov/17455113/	yes [Ki 1.5 uM]
OATP1B1 785	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/25653502/\|https://pubmed.ncbi.nlm.nih.gov/23139378/\|https://pubmed.ncbi.nlm.nih.gov/17523051/\|https://pubmed.ncbi.nlm.nih.gov/16316932/\|https://pubmed.ncbi.nlm.nih.gov/17470528/	yes [Ki 14.2 uM]
CYP2C9 1747	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11719730/ \|https://pubmed.ncbi.nlm.nih.gov/11602509/	yes [Ki 5.8 uM]	yes (co-administration study) Comment: [PMID:11719730]:Gemfibrozil modestly increases the plasma concentrations of glimepiride. This may be caused by inhibition of CYP2C9. Sources: https://pubmed.ncbi.nlm.nih.gov/11719730/ \|https://pubmed.ncbi.nlm.nih.gov/11602509/
CYP1A2 1620	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	yes
CYP2C19 1484	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11602509/	yes
OATP1B3 700	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/25653502/\|https://pubmed.ncbi.nlm.nih.gov/17470528/	yes
OATP2B1 124	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/17470528/	yes
CYP2C8 923	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/25941268/\|https://pubmed.ncbi.nlm.nih.gov/22472994/	yes	yes (co-administration study) Comment: [PMID:22472994]: CYP2C8 inactivation by gemfibrozil caused dose-dependent increases in AUC of repaglinide Sources: https://pubmed.ncbi.nlm.nih.gov/25941268/\|https://pubmed.ncbi.nlm.nih.gov/22472994/

Drug as victim

Target	Modality	Activity
UGT2B7 387	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	major
P-gp 1491	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/14698041/	no
UGT1A10 289	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A4 345	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A6 306	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A7 235	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A8 282	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT2B15 202	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	no
UGT1A1 417	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT1A3 421	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT1A9 378	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT2B17 212	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes
UGT2B4 248	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/17670842/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:5296	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5296
ChemicalBook	CB9154247	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9154247
MolPort	MolPort-001-794-413	https://www.molport.com/shop/molecule-link/MolPort-001-794-413
Selleck Chemicals	Gemfibrozil(Lopid)	http://www.selleckchem.com/products/Gemfibrozil(Lopid).html
ZINC	ZINC000001530641	http://zinc15.docking.org/substances/ZINC000001530641
eMolecules	538915	https://www.emolecules.com/cgi-bin/more?vid=538915

PubMed

Title	Date	PubMed
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.	2001	11795072
Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction.	2001	11552053
Rhabdomyolysis and acute renal failure following a switchover of therapy between two fibric acid derivatives.	2001 Aug	11764054
[Fatal rhabdomyolysis caused by cerivastatin].	2001 Aug	11584446
Inhibitory action of gemfibrozil on cholesterol absorption in rat intestine.	2001 Aug	11483622
Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men.	2001 Aug	11477498
Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.	2001 Aug	11473572
Bayer decides to withdraw cholesterol lowering drug.	2001 Aug 18	11509419
Baycol withdrawn from market.	2001 Aug 21	11521677
Altered expression of the carboxylesterases ES-4 and ES-10 by peroxisome proliferator chemicals.	2001 Aug 28	11522369
[Lipid-lowering drugs].	2001 Dec	11778457
Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil.	2001 Dec	11733637
Treatment for the procoagulant state in type 2 diabetes.	2001 Dec	11727398
Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?	2001 Dec	11722675
Determination of drugs in surface water and wastewater samples by liquid chromatography-mass spectrometry: methods and preliminary results including toxicity studies with Vibrio fischeri.	2001 Dec 14	11771838
Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial.	2001 Dec 20	11788126
[Fibrates in the secondary prevention of ischemic cardiopathy].	2001 Jan-Mar	11565320
Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.	2001 Jul	11583069
[Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].	2001 Jul	11515276
The effects of lipid-lowering agents on acute renal allograft rejection.	2001 Jul 27	11477342
Statin-fibrate combination therapy.	2001 Jul-Aug	11485144
Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells.	2001 Nov	11816722
Effect of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental hypertriglyceridaemia and hypercholesterolaemia induced by Triton WR 1339 (tyloxapol) in mice.	2001 Nov	11731925
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.	2001 Nov	11719730
PPARS, metabolic disease and atherosclerosis.	2001 Nov	11712864
Clinical inquiries. What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?	2001 Nov	11711005
Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.	2001 Nov	11701466
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?	2001 Nov	11694861
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?	2001 Nov	11684067
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.	2001 Nov	11602509
Effects of fenofibrate and gemfibrozil on plasma homocysteine.	2001 Nov 24	11734263
Effects of fenofibrate and gemfibrozil on plasma homocysteine.	2001 Nov 24	11734262
Statin-associated myopathy.	2001 Nov 5	11758079
Fatal rhabdomyolysis caused by lipid-lowering therapy.	2001 Oct	11702815
Serum magnesium status during lipid-lowering drug treatment in non-insulin-dependent diabetic patients.	2001 Oct	11586485
Cyclic nucleotides in platelets of genetically hypertriglyceridemic and hypertensive rats. Thrombin and nitric oxide responses are unrelated to plasma triglyceride levels.	2001 Oct 1	11583736
[Cerivastatin and gemfibrozil: a dangerous combination].	2001 Oct 15	11602128
Molecular basis for the effect of lipid lowering drugs on growth factors after de-endothelialization.	2001 Sep	11780395
[Cholestatic hepatitis caused by gemfibrozil].	2001 Sep	11767440
Cerivastatin and gemfibrozil-associated rhabdomyolysis.	2001 Sep	11573847
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.	2001 Sep	11570656
Is the relationship between adipose tissue and waist girth altered by weight loss in obese men?	2001 Sep	11557833
New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol.	2001 Sep	11487447
[Severe rhabdomyolysis associated with cerivastatin and gemfibrozil].	2001 Sep 15	11562335
Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats.	2001 Sep 15	11551527
Bayer pulls cerivastatin (Baycol) from market.	2001 Sep 4	11563216
[Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].	2001 Sep-Oct	11795020
Therapy and clinical trials.	2002 Feb	11790971
Sexual dysfunction secondary to gemfibrozil.	2002 Jan	11794424
Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.	2002 Jan 28	11802751

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose for adults is 1200 mg administered in two divided doses 30 minutes before the morning and evening meals

Route of Administration: Oral

In Vitro Use Guide

Sustained potent reduction of [Ca²⁺]i in cultured rat VSMCs was observed with Gemfibrozil 50mg/L

Substance Class	Chemical Created by `admin` on `Fri Dec 16 16:49:27 UTC 2022` Edited by `admin` on `Fri Dec 16 16:49:27 UTC 2022`
Record UNII	Q8X02027X3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GEMFIBROZIL

Official Name

English

GEMFIBROZIL [IARC]

Common Name

English

Gemfibrozil [WHO-DD]

Common Name

English

GEMFIBROZIL [HSDB]

Common Name

English

2,2-DIMETHYL-5-(2,5-XYLYLOXY) VALERIC ACID

Systematic Name

English

gemfibrozil [INN]

Common Name

English

GEMFIBROZIL [EP MONOGRAPH]

Common Name

English

GEMFIBROZIL [MART.]

Common Name

English

GEMFIBROZIL [USAN]

Common Name

English

GEMFIBROZIL [USP-RS]

Common Name

English

GEMFIBROZIL [JAN]

Common Name

English

NSC-757024

Code

English

GEMFIBROZIL [ORANGE BOOK]

Common Name

English

GEMFIBROZIL [MI]

Common Name

English

GEMFIBROZIL [INCI]

Common Name

English

CI-719

Code

English

GEMFIBROZIL [USP MONOGRAPH]

Common Name

English

PENTANOIC ACID, 5-(2,5-DIMETHYLPHENOXY)-2,2-DIMETHYL-

Common Name

English

LOPID

Brand Name

English

GEMFIBROZIL [VANDF]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

834821